Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Primary Sclerosing Cholangitis

Diseases of the Digestive System

Primary sclerosing cholangitis is a long-term, progressive disease of the liver and gallbladder in which the bile ducts become inflamed and scarred, narrowing the passages that normally carry bile needed for digestion. Its cause is uncertain; researchers suspect an autoimmune process, though the disease does not respond predictably to immune-suppressing drugs, and genetic predisposition, immune dysfunction, and an abnormal makeup of gut bacteria are all thought to contribute. About three-quarters of patients also have inflammatory bowel disease, usually ulcerative colitis, and while nearly half have no symptoms at first and are found only through abnormal liver tests, others develop severe itching, fatigue, jaundice, abdominal pain, and an enlarged liver or spleen, along with recurrent bile duct infections. It substantially raises the risk of bile duct cancer, about 400 times the general population's risk, and median survival from diagnosis to liver transplant or death from the disease is roughly 21 years, though this varies widely by individual case.

Facts
Classification
Body System
Digestive System 1
ICD-10 Chapter
XI: Diseases of the Digestive System 1
Communicable or Non-communicable
Non-Communicable 2
Transmission Route
Non-Transmissible 2
Causative Agent
Causative Agent (category)
Autoimmune 2
Sources
1. Wikipedia: ICD-10
WikipediaList of chapters, Chapter XI
Quote, List of chapters, Chapter XI
Diseases of the digestive system
View the Source
2. Primary sclerosing cholangitis (Wikipedia)
Wikipedia
  • Infobox medical condition, causes
    Unknown; most likely autoimmune
  • Article text - causative-agent
    Although PSC is thought to be caused by autoimmune disease, it does not demonstrate a clear response to immunosuppressants.
View the Source
Wikidata: Primary Sclerosing Cholangitis
Wikidata Q1058608, class allow-list match (w-wdresolver-0926)View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.